a Department of Biochemistry, Biosciences Center, Federal University of Rio Grande do Norte , Natal , Brazil.
b Department of Collective Health, Federal University of Rio Grande do Norte , Natal , Brazil.
J Enzyme Inhib Med Chem. 2019 Dec;34(1):405-419. doi: 10.1080/14756366.2018.1542387.
The increase in non-communicable chronic diseases has aroused interest in the research of adjuvants to the classic forms of treatments. Obesity and metabolic syndrome are the main targets of confrontation because they relate directly to other chronic diseases. In this context, trypsin inhibitors, molecules with wide heterologous application, appear as possibilities in the treatment of overweight and obesity due to the action on satiety related mechanisms, mainly in the modulation of satiety hormones, such as cholecystokinin. In addition, trypsin inhibitors have the ability to also act on some biochemical parameters related to these diseases, thus, emerging as potential candidates and promising molecules in the treatment of the obesity and metabolic syndrome. Thus, the present article proposes to approach, through a systematic literature review, the advantages, disadvantages and viabilities for the use of trypsin inhibitors directed to the treatment of overweight and obesity.
慢性非传染性疾病的增加引起了人们对经典治疗方法的辅助手段的研究兴趣。肥胖和代谢综合征是对抗的主要目标，因为它们与其他慢性疾病直接相关。在这种情况下，胰蛋白酶抑制剂作为具有广泛异源应用的分子，由于其对饱腹感相关机制的作用，主要是对饱腹感激素的调节，如胆囊收缩素，出现在超重和肥胖治疗的可能性。此外，胰蛋白酶抑制剂还具有作用于与这些疾病相关的一些生化参数的能力，因此，作为肥胖和代谢综合征治疗的潜在候选药物和有前途的分子。因此，本文通过系统的文献回顾，提出了针对超重和肥胖治疗的胰蛋白酶抑制剂的使用的优点、缺点和可行性。
